LeMaitre Vascular, Inc.

LMAT • Medical - Instruments & Supplies

$83.40

— 0.00 (0.00%)

ResultadosÚltimo reporte: 30 jun 2026

PERFIL MUY FAVORABLEExcelenteConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Alta calidad del negocio, con crecimiento y flujo de caja que respaldan el caso. La valoración todavía importa, pero el historial de ratios es favorable.

Capitalización

$2.04B

Crecimiento

8.0%

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Márgenes estables o en mejora · 23.1%Crecimiento positivo de ingresos · 10.9%Flujo de caja libre positivo · 3.29Flujo de caja libre consistente · 5/5Nivel de deuda manejable · 0.47

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 7 ago 2026, 1:01 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$83.40

Change0.00%

Shares Out24.50M

Market Cap$2.04B

Enterprise Value$1.84B

52W Range78.65 - 118.01

Beta0.52

P/E31.12

P/S7.79

P/B4.86

P/FCF27.68

EV/Sales7.00

Price$83.40

Change0.00%

Shares Out24.50M

Market Cap$2.04B

Enterprise Value$1.84B

52W Range78.65 - 118.01

Beta0.52

P/E31.12

P/S7.79

P/B4.86

P/FCF27.68

EV/Sales7.00

EV/EBITDA20.42

EV/FCF24.88

Earnings Yield3.21%

FCF Yield3.61%

Dividend Yield0.76%

Gross Margin71.53%

Oper. Margin27.21%

Profit Margin23.13%

Debt/Eq0.47

Current Ratio12.89

Quick Ratio10.95

Revenue 5Y7.96%

Target$115.00

Target Upside37.89%

Target Median$115.00

Target Range95.00 - 135.00

Volume653.08K

Avg Volume305.61K

EPS Surprise0.02

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

90/100

Fortaleza financiera

Deuda, caja, estabilidad

93/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

48/100

Por qué este puntaje▼

Márgenes estables o en mejora · 23.1%Crecimiento positivo de ingresos · 10.9%Flujo de caja libre positivo · 3.29Flujo de caja libre consistente · 5/5Nivel de deuda manejable · 0.47Liquidez saludable · 12.89

Analyst view

Analyst sentiment and price target

LMAT

Analyst sentiment

Based on 20 analyst votes · 2026-10-20

85/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-07

Bajo

$95.00

Promedio

$115.00

Mediana

$115.00

Alto

$135.00

Resumen de la compañía

IPO: 10/19/2006

Industria: Medical - Instruments & Supplies

P/B i: 4.86

Deuda / Patrimonio i: 0.47

Margen operativo: 27.21%

Margen neto: 23.13%

ROE i: -

ROIC: -

Salud financiera

Puntaje19 / 20

Deuda / Patrimonio: 0.47

Ratio corriente: 12.89

Ratio rápido: 10.95

Estado: Strong

Transacciones internas

Actividad reciente de ejecutivos e insiders

LeMaitre George W

Transacción: 06/04/2026

COMPRA

Cambio

—

Precio

Not reported

Presentación

06/05/2026

Tipo

COMPRA

LeMaitre George W

Transacción: 06/04/2026

COMPRA

Cambio

+11,974

Precio

Not reported

Presentación

06/05/2026

Tipo

COMPRA

Kamke Trent G

Transacción: 06/04/2026

COMPRA

Cambio

—

Precio

Not reported

Presentación

06/05/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
LeMaitre George W	COMPRA	—	Not reported	06/04/2026	06/05/2026
LeMaitre George W	COMPRA	+11,974	Not reported	06/04/2026	06/05/2026
Kamke Trent G	COMPRA	—	Not reported	06/04/2026	06/05/2026
Roberts David B	COMPRA	—	Not reported	06/04/2026	06/05/2026
LeBlanc Dorian Paul	COMPRA	—	Not reported	06/04/2026	06/05/2026
Pellegrino Joseph P JR	COMPRA	—	Not reported	06/04/2026	06/05/2026
SHADAN MARTHA	COMPRA	—	Not reported	06/04/2026	06/05/2026
Roush John A	COMPRA	—	Not reported	06/04/2026	06/05/2026
O'Connor John James	COMPRA	—	Not reported	06/04/2026	06/05/2026
Jasinski Lawrence J	COMPRA	—	Not reported	06/04/2026	06/05/2026
Kamke Trent G	VENTA	-2,928	$107.00	05/08/2026	05/11/2026
LeMaitre George W	VENTA	-27,881	$108.69	05/08/2026	05/11/2026
Jasinski Lawrence J	VENTA	-865	$101.12	05/07/2026	05/11/2026
Jasinski Lawrence J	VENTA	-3,943	$110.00	05/07/2026	05/11/2026
Ross Bridget A	VENTA	-3,444	$48.60	05/07/2026	05/11/2026
Ross Bridget A	VENTA	-5,044	$111.10	05/07/2026	05/11/2026
LeMaitre George W	VENTA	-18,600	$107.64	05/07/2026	05/11/2026
Pellegrino Joseph P JR	VENTA	-2,941	$35.48	04/22/2026	04/23/2026
Pellegrino Joseph P JR	COMPRA	+2,941	$35.48	04/22/2026	04/23/2026
LeMaitre George W	COMPRA	—	Not reported	03/26/2026	03/30/2026

Sobre la compañía

LeMaitre Vascular, Inc.

Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.

Fuente - Link

Competidores

ACHC ATRC AVAH HAE INSP NHC PAHC PRCT QDEL TWST

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026

BURLINGTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2026 financial results on Wednesday, November 4, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook.

GlobeNewsWire

LeMaitre Vascular: The Q2 Miss Hides A Stronger Acquisition Machine

LeMaitre Vascular is rated a "Strong Buy" due to its robust M&A-driven business model, high margins, and recent valuation compression. LMAT's strategic shift to larger, higher-multiple acquisitions has improved its success rate to 80% and driven margin expansion, with gross margin rising from 65% to 72%. The company's healthy balance sheet, $376M in cash/short-term investments, and experienced management underpin its ability to pursue disciplined, accretive deals.

Seeking Alpha

LeMaitre Vascular Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Customer Data Is Exposed

National class action law firm offers free, confidential case evaluations to LeMaitre Vascular investors, tenants, partners, and others whose personal information may have been exposed in the reported data breach. NEWTOWN, Pa.

PRNewsWire

PAHC or LMAT: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and LeMaitre Vascular (LMAT). But which of these two stocks is more attractive to value investors?

Zacks Investment Research

LeMaitre to Participate at Upcoming Investor Conferences in September

BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-05	0.66	0.68	0.02
2026-02-25	0.67	0.68	0.01
2025-11-06	0.564	0.62	0.056
2025-08-05	0.57	0.6	0.03
2025-05-01	0.5	0.48	-0.02
2025-02-27	0.49	0.49	0
2024-10-31	0.44	0.49	0.05
2024-08-01	0.47	0.52	0.05
2024-05-02	0.39	0.44	0.05
2024-02-27	0.36	0.38	0.02
2023-11-01	0.3	0.33	0.03
2023-08-01	0.32	0.36	0.04